PolyMedix was founded in 2002, based on proprietary computational drug design technology which we have exclusively licensed from the University of Pennsylvania. This technology is based on the work of Drs. William DeGrado and Michael Klein, who are members of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Royal Society. Our proprietary de novo drug design approach involves using protein targets with well-understood physical structures and biological activity, and designing small molecule compounds that mimic or regulate the activity of these targets. We believe our structure-based approach allows us to rationally design novel product candidates and greatly improve the efficiency of new drug discovery.

Scientific Founders and Advisors
Dr. William DeGrado is Raizus Professor of Biochemistry and Biophysics at the Medical School of the University of Pennsylvania, has over 250 publications and a multitude of patents. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and has earned the prestigious Merryfield and Hirschman Chemistry Awards.

Dr. Michael Klein is Director of the prestigious Laboratory for Research on the Structure of Matter at the University of Pennsylvania, and has over 500 publications over the past 40 years. He is a member of the Royal Society and the American Academy of Arts and Sciences.

Dr. Gregory Tew is Associate Professor at the School of Polymer Sciences and Engineering at the University of Massachuseets. He is an expert in polymeric materials science, and recipient of numerous awards including the PECASE.

return to top ^